Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Multicenter, Randomized, Subject and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.

NCT05293522 is registered in ClinicalTrials.gov with Neuraptive Therapeutics Inc. as lead sponsor.

NCT NCT05293522
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05293522 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Multicenter, Randomized, Subject and Evaluator Blinded, Controlled Study Evaluating the Safety and Efficacy of NTX-001 Compared to Standard of Care in the Treatment and Prevention of Facial Paralysis Requiring Surgical Repair.
Lead sponsor
Neuraptive Therapeutics Inc.
Phase
Phase 2
Overall status
Terminated
Start date
July 12, 2022
Completion date
August 22, 2023
Enrollment
2 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

facial paralysis